Acalisib - CAS 870281-34-8
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Acalisib
Catalog Number:
870281-34-8
Synonyms:
GS-9820; GS9820; GS 9820; CAL-120; CAL 120; CAL120; Acalisib; UNII-OVW60IDW1D.
CAS Number:
870281-34-8
Description:
Acalisib, also known as GS-9820,  is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. p110beta/delta PI3K inhibitor GS-9820 inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.
COA:
Inquire
MSDS:
Inquire
Targets:
PI3K
Current Developer:
Gilead Sciences
Chemical Structure
CAS 870281-34-8 Acalisib

Related PI3K Products


TGR-1202 hydrochloride
(CAS: 1532533-78-0)

TGR-1202 hydrochloride is the hydrochloride salt of TGR-1202.TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which i...

CAS 956958-53-5 XL147

XL147
(CAS: 956958-53-5)

Pilaralisib is a Class 1 phosphatidylinositol 3 kinase (PI3K) family inhibitor. It is an orally bioavailable small molecule, targeting the class I PI3K family o...

CAS 1202777-78-3 BKM120

BKM120
(CAS: 1202777-78-3)

BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...

CAS 1431697-74-3 CAL-130

CAL-130
(CAS: 1431697-74-3)

CAL-130 is a potent and selective PI3K gamma and delta inhibitor with potential anticancer activity. Constitutive phosphoinositide 3-kinase (PI3K)/Akt activatio...

AM-8508
(CAS: 1338483-67-2)

AM-8508 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-8508 exhibits good cellular potency (in vitro pAKT IC50 = 4.6 nM ) and excellen...

LY-3023414
(CAS: 1386874-06-1)

LY3023414, a quinoline derivative, has been found to be a PI3Kα and mTOR inhibitor that could influence cell proliferation and cycle of tumor cells. It was just...

AM-9635
(CAS: 1338483-10-5)

AM-9635 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-9635 exhibits good cellular potency (in vitro pAKT IC50 = 4.2 nM ). AM-9635 can...

CAS 1332075-63-4 PI3k(delta) inhibitor 1

PI3k(delta) inhibitor 1
(CAS: 1332075-63-4)

PI3kδ inhibitor 1 is a potent and selective inhibitor of isoform of PI3Kδ; useful for treating disorders mediated by lipid kinases such as inflammation, immunol...

CAS 1276105-89-5 CNX-1351

CNX-1351
(CAS: 1276105-89-5)

CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...

CAS 900515-16-4 AS-252424

AS-252424
(CAS: 900515-16-4)

AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.

CAS 677297-51-7 TG100-115

TG100-115
(CAS: 677297-51-7)

TG100-115, inhibited PI3K γ and -δ(IC50 values of 83 and 235 nM, respectively), whereas both PI3Kα and -β were relatively unaffected (IC50 values>1 μM). As a ga...

CAS 663619-89-4 TGX-221

TGX-221
(CAS: 663619-89-4)

TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit. Recent studies showed that TGX-221 has antiproliferat...

CAS 1372540-25-4 GSK2636771

GSK2636771
(CAS: 1372540-25-4)

GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineopla...

CAS 1254036-66-2 GSK2292767

GSK2292767
(CAS: 1254036-66-2)

GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials....

GDC-0326
(CAS: 1282514-88-8)

GDC-0326 is a selective PI3Kα (α-Isoform of Phosphoinositide 3-Kinase) inhibitor. GDC-0326 is highly selective over other kinases. It has low plasma CL in human...

Seletalisib
(CAS: 1362850-20-1)

Seletalisib is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by UCB.It is a Immunomodulator. Phaes I clinical trials for Plaque psoriasis...

CAS 677338-12-4 PIK-90

PIK-90
(CAS: 677338-12-4)

PIK-90 is a potent PI3K inhibitor.

CAS 1007207-67-1 CH5132799

CH5132799
(CAS: 1007207-67-1)

CH5132799 is a novel class I PI3K inhibitor, which exhibited a strong inhibitory activity especially against PI3K; (IC(50)=0.014 uM). In human tumor cell lines ...

CAS 1245537-68-1 BGT226 (NVP-BGT226)

BGT226 (NVP-BGT226)
(CAS: 1245537-68-1)

BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.

AZD6482 (S-isomer)
(CAS: 1173900-37-2)

This active molecular is the S-configuration isomer of AZD6482. AZD6482 is a selective, ATP competitive PI3Kβ inhibitor and IC50 value is 0.01 μm. Meanwhile, AZ...

Reference Reading


1.[Analoghi sintetici dell'ormone di rilascio dell'ormone luteinizzante per il trattamento del carcinoma prostatico localmente avanzato o metastatico: analisi dei costi diretti e indiretti nello scenario italiano].
Fadda V, Maratea D. Recenti Prog Med. 2015 Dec;106(12):634-40. doi: 10.1701/2094.22656.
Riassunto. Introduzione. Gli analoghi sintetici dell'ormone di rilascio dell'ormone luteinizzante (Lh-Rh) sono utilizzati per diverse indicazioni cliniche. I dati di outcome non riportano differenze significative in termini di efficacia tra i diverse analoghi di sintesi Lh-Rh. Materiali e metodi. La ricerca di letteratura è stata eseguita inserendo le seguenti parole chiave nelle biblioteche biomediche online (PubMed) e nei database online delle Agenzie regolatorie (EMA e FDA): "LHRH agonist AND prostatic cancer", "androgen deprivation therapy", "androgen suppression", "buserelin", "leuprorelin", "goserelin", "triptorelin", "degarelix". Nei costi diretti sono stati inclusi i costi relativi alle visite specialistiche di controllo, il costo dell'esame del PSA e il costo del farmaco. Tra i costi indiretti sono stati inclusi le giornate lavorative perse dal paziente. Risultati. Considerando lo schema terapeutico intermittente per tutti i farmaci considerati, il costo di trattamento più basso è attribuibile alla formulazione di Eligard 22,5 mg mentre la spesa più alta si registra con la somministrazione di Firmagon.